Search research articles
Contact Us
Filters
Showing results (191-200 of 302) with videos related to
Page
of 31
Sort By:
Nature Communications
|
October 26, 2017
BCL-X<sub>L</sub> directly modulates RAS signalling to favour cancer cell stemness
Sophie de Carné Trécesson, Frédérique Souazé, Agnès Basseville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
Breast Cancer Research and Treatment
|
February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Andrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
Clinical Breast Cancer
|
October 4, 2025
Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database Study
Katia Mahiou, Claire Bonneau, Charles Coutant, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)
Mario Campone, Thomas Bachelot, Isabelle Treilleux, et al.
Nature Communications
|
January 16, 2020
STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment
Steven Lohard, Nathalie Bourgeois, Laurent Maillet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
Javier Cortes, Linda Vahdat, Joanne L Blum, et al.
International Journal of Oncology
|
May 4, 2012
Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study
Françoise Descotes, Pascal Jézéquel, Frédérique Spyratos, et al.
The Oncologist
|
July 31, 2010
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study
Jean-Marc Extra, Eric C Antoine, Anne Vincent-Salomon, et al.
Nature Communications
|
July 15, 2022
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
Aditya Bardia, Sarat Chandarlapaty, Hannah M Linden, et al.
Page
of 31
Search research articles
Search
Showing results (191-200 of 302) with videos related to
Sort By:
Page
of 31
Nature Communications
|
October 26, 2017
BCL-X<sub>L</sub> directly modulates RAS signalling to favour cancer cell stemness
Sophie de Carné Trécesson, Frédérique Souazé, Agnès Basseville, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
Breast Cancer Research and Treatment
|
February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Andrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
Clinical Breast Cancer
|
October 4, 2025
Effect of Breast Surgery on Quality of Life in BRCA Mutation Carriers With Invasive Breast Cancer: A CANTO Database Study
Katia Mahiou, Claire Bonneau, Charles Coutant, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)
Mario Campone, Thomas Bachelot, Isabelle Treilleux, et al.
Nature Communications
|
January 16, 2020
STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment
Steven Lohard, Nathalie Bourgeois, Laurent Maillet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
Javier Cortes, Linda Vahdat, Joanne L Blum, et al.
International Journal of Oncology
|
May 4, 2012
Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study
Françoise Descotes, Pascal Jézéquel, Frédérique Spyratos, et al.
The Oncologist
|
July 31, 2010
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study
Jean-Marc Extra, Eric C Antoine, Anne Vincent-Salomon, et al.
Nature Communications
|
July 15, 2022
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
Aditya Bardia, Sarat Chandarlapaty, Hannah M Linden, et al.
Page
of 31